PAX1 and hypoparathyroidism: It is possible to hypothesize that PAX1 dosage alteration can contribute specifically to the otolaryngological manifestations, such as the hearing loss observed in patient P5 and to the dysmorphic auricular appendix in patient P4, as well to the hypoparathyroidism and immunological alterations found in both sisters, which is usually observed in 22.11.2DS.